about
Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor HeteromerizationDifferential neuroprotective effects of 5'-deoxy-5'-methylthioadenosineA genomics approach identifies selective effects of trans-resveratrol in cerebral cortex neuron and glia gene expression.Health benefits of methylxanthines in cacao and chocolate.Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors.Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signallingPhenyl acyl acids attenuate the unfolded protein response in tunicamycin-treated neuroblastoma cellsLifelong expression of apolipoprotein D in the human brainstem: correlation with reduced age-related neurodegenerationThe relevance of theobromine for the beneficial effects of cocoa consumption.Age-related changes of apolipoprotein D expression in female rat central nervous system with chronic estradiol treatmentRegional and Gender Study of Neuronal Density in Brain during Aging and in Alzheimer's Disease.Challenges in the development of heteromer-GPCR-based drugs.G-protein-coupled receptor heteromers as key players in the molecular architecture of the central nervous system.The potential of methylxanthine-based therapies in pediatric respiratory tract diseases.Health benefits of methylxanthines in neurodegenerative diseases.Apolipoprotein D subcellular distribution pattern in neuronal cells during oxidative stress.Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer's disease.GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells.Oxidative stress induces apolipoprotein D overexpression in hippocampus during aging and Alzheimer's disease.Apolipoprotein D synthesis progressively increases in frontal cortex during human lifespan.Chemical rules on the assessment of antioxidant potential in food and food additives aimed at reducing oxidative stress and neurodegeneration.Amyloid-β25-35 induces apolipoprotein D Synthesis and growth arrest in HT22 hippocampal cells.Neurochemical evidence supporting dopamine D1-D2 receptor heteromers in the striatum of the long-tailed macaque: changes following dopaminergic manipulationDetection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonismCB1 and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum.Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum.Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors.L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.The Epigenetic Cytocrin Pathway to the Nucleus. Epigenetic Factors, Epigenetic Mediators, and Epigenetic Traits. A Biochemist Perspective.Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay.Highly selective and fast diagnosis of Alzheimer's disease hallmark lesions using Congo Red in isopropyl alcoholic solution.Apo J and Apo D: Complementary or Antagonistic Roles in Alzheimer's Disease?L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice.Expression Pattern of Myelin-Related Apolipoprotein D in Human Multiple Sclerosis LesionsGender differences in apolipoprotein D expression during aging and in Alzheimer diseaseApoD, a glia-derived apolipoprotein, is required for peripheral nerve functional integrity and a timely response to injuryTargeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's DiseaseAntioxidants versus Food Antioxidant Additives and Food PreservativesLessons on Differential Neuronal-Death-Vulnerability from Familial Cases of Parkinson's and Alzheimer's Diseases
P50
Q26749791-BE0FE19B-3E0F-4096-9DF1-94B3C34236E4Q27317185-0D603D3F-E115-493A-8912-50EBBE70A3C4Q33602768-2F8603A7-E207-4A22-9134-8F6A7247B140Q33602768-7C137420-0CED-4737-AF4B-9BA0DC59CE37Q34379254-EC9076D8-9567-49A1-AEA1-7C2095B162FFQ34650465-5CB899D0-A483-4BE3-8F1E-ACF957BE2E56Q34953430-0209D8DF-FCF8-461B-8E4F-AA543ADC4D0FQ34970563-FF4373FB-128E-4A66-BBF5-DB9C8384D8F4Q35027790-1E330A4E-B199-49AD-9867-1FDB13B39215Q35104091-EC90AA32-5F4F-4644-B0DF-F04486A262F0Q36927513-430784A7-B6E7-45D3-8395-9184A6B5524DQ37250497-CDFF406D-E219-475C-B6FC-07D6A89B346FQ38105687-12136C30-3BCE-4F2A-8133-1C3DD483AA64Q38210280-88DD2461-354F-47B6-A517-291EF5DD930CQ38734968-8FA31E33-46FF-4FBB-B2FE-AE739D4E5DC3Q38772021-731BC683-F788-4D70-BF6D-7D9C228F5007Q38877836-56E47EA4-D5C4-4E4D-AAF9-96EB36931457Q38965582-40EE25EA-1277-43AD-B485-DD18F1EF6244Q39022744-DDCAA815-7B19-4166-B95E-C35735AD9728Q39169270-E1E76C6C-C368-4FDF-A7ED-25AAC26FFE74Q39316146-B63C0F2B-D088-4409-9097-1480851ED452Q39336519-29243C64-67DD-416A-804B-7BE660A92BBCQ39383783-A45E5C15-61CB-461F-876D-5F818799BC80Q39405720-736D9654-1243-4100-96B6-604DD03727A3Q42095959-7AB2E1A7-5DEB-4DB2-823D-50BD0580ED2CQ42461317-E4C7E996-727F-4F39-9DF0-3237D5307ED4Q42477197-F2FCEFFD-F9F1-4D45-A259-A3146EFFC3C9Q43217955-9DA10233-B8B6-449E-B60F-4AF1D5A84526Q45228276-135AA90F-F8FA-40D1-906E-22E8C6296CBCQ47111308-6B6D24B7-1DD4-45A3-85B9-8D343AB5E1A7Q48041725-89144C48-EDE5-4F6E-9EEB-14A4050A5813Q48142015-C727D394-1943-4B13-8FF1-753078963C55Q48724281-0FEBA8DD-A1A0-47DC-8632-9A2B06E4A7BAQ48873583-6BCE2B4D-1330-49AC-9FFF-54BA177AC255Q52565458-8D74F056-EA88-4448-9E30-B24B68DE4BFCQ58728967-77E85392-9073-4E7F-A900-B96476F821B2Q59386592-A06EEB24-0273-4D3D-BD6D-2C736F819B7AQ59386593-6248B0CF-58AA-4A98-A83C-39FE3D726F56Q91245012-8ADA4307-F3A3-4667-A32E-CD8CB3E0F350Q91254704-F2A1EB70-AB57-4F14-BCA3-E0DEB3E9FABA
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Eva Martínez-Pinilla
@ast
Eva Martínez-Pinilla
@en
Eva Martínez-Pinilla
@es
Eva Martínez-Pinilla
@nl
Eva Martínez-Pinilla
@sl
type
label
Eva Martínez-Pinilla
@ast
Eva Martínez-Pinilla
@en
Eva Martínez-Pinilla
@es
Eva Martínez-Pinilla
@nl
Eva Martínez-Pinilla
@sl
altLabel
E Martinez-Pinilla Eva Martinez, E Martínez
@en
prefLabel
Eva Martínez-Pinilla
@ast
Eva Martínez-Pinilla
@en
Eva Martínez-Pinilla
@es
Eva Martínez-Pinilla
@nl
Eva Martínez-Pinilla
@sl
P1053
C-7907-2013
P106
P1153
55745792500
P21
P2798
P31
P3829
P496
0000-0002-0572-0926